Key result
Engineered Bifidobacterium longum reduces cardiac inflammation and viral titers in murine viral myocarditis.
Why the study?
Research is needed on how to stably express interferon-α in the gut for treatment of viral infections such as coxsackievirus B3-induced myocarditis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for engineered probiotics in murine viral myocarditis; leaves open human translation pending clinical trials.
Multiple reports have claimed that low-dose orally administered interferon (IFN)-α is beneficial in the treatment of many infectious diseases and provides a viable alternative to high-dose intramuscular treatment. However, research is needed on how to express IFN stably in the gut. Bifidobacterium may be a suitable carrier for human gene expression and secretion in the intestinal tract for the treatment of gastrointestinal diseases. We reported previously that Bifidobacterium longum can be used as a novel oral delivery of IFN-α. IFN-transformed B. longum can exert an immunostimulatory role in mice; however the answer to whether this recombinant B. longum can be used to treat virus infection still remains elusive. Here, we investigated the efficacy of IFN-transformed B. longum administered orally on coxsackie virus B3 (CVB3)-induced myocarditis in BALB/c mice. Our data indicated that oral administration of IFN-transformed B. longum for 2 weeks after virus infection reduced significantly the severity of virus-induced myocarditis, markedly down regulated virus titers in the heart, and induced a T helper 1 cell pattern in the spleen and heart compared with controls. Oral administration of the IFN-transformed B. longum, therefore, may play a potential role in the treatment of CVB3-induced myocarditis.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2011) studied Coxsackievirus B3-induced myocarditis (n=43). Oral administration of interferon-α2b-transformed Bifidobacterium longum vs. Saline, control plasmid-transformed B. longum, or intramuscular pegylated IFN-α2b was evaluated on Cardiac inflammatory area and virus titers at day 14 (p=<0.01). Oral administration of interferon-α2b-transformed Bifidobacterium longum reduced the cardiac inflammatory area and virus titers in mice with coxsackievirus B3-induced myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: